A detailed history of Point72 (Difc) LTD transactions in Bio Atla, Inc. stock. As of the latest transaction made, Point72 (Difc) LTD holds 48 shares of BCAB stock, worth $75. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48
Previous 17,261 99.72%
Holding current value
$75
Previous $23.6 Million 99.64%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.17 - $2.05 $20,139 - $35,286
-17,213 Reduced 99.72%
48 $84,000
Q2 2024

Aug 14, 2024

BUY
$1.37 - $3.92 $23,647 - $67,663
17,261 New
17,261 $23.6 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $57M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Point72 (Difc) LTD Portfolio

Follow Point72 (Difc) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 (Difc) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 (Difc) LTD with notifications on news.